Detalhe da pesquisa
1.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313048
2.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int
; 42(11): 2538-2547, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986902
3.
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together.
Curr Opin Oncol
; 33(4): 386-394, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33867478
4.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
JHEP Rep
; 6(2): 100982, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38274490
5.
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
Ther Adv Med Oncol
; 15: 17588359221148029, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36643654
6.
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
JHEP Rep
; 5(1): 100620, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578451
7.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hepatol Int
; 17(4): 904-914, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005953
8.
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
World J Gastrointest Oncol
; 15(11): 1900-1912, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38077640
9.
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.
J Hepatocell Carcinoma
; 9: 1011-1027, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36128575
10.
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
Expert Opin Investig Drugs
; 31(4): 425-435, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35152830
11.
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials.
Expert Opin Investig Drugs
; 31(4): 401-413, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35072565
12.
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study.
J Pers Med
; 12(2)2022 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35207692
13.
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Cancers (Basel)
; 14(23)2022 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497316
14.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Eur J Cancer
; 175: 204-213, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36148739
15.
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.
Drugs Aging
; 38(7): 579-591, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152589
16.
Current options and future directions of systemic therapy for advanced biliary tract cancer.
Explor Target Antitumor Ther
; 2(5): 416-433, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045701
17.
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
Expert Rev Anticancer Ther
; 21(9): 927-939, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167423
18.
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges.
J Hepatocell Carcinoma
; 8: 177-191, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824862
19.
Hysteroscopic approach to uterine cervical canal stenosis.
Minerva Obstet Gynecol
; 73(2): 185-192, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249822
20.
Retooling treatment in oligometastatic oesophageal cancer.
Lancet Gastroenterol Hepatol
; 9(1): 5-7, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980923